The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

Sponsor
Abbott (Industry)
Overall Status
Completed
CT.gov ID
NCT00002331
Collaborator
(none)
18
13.9

Study Details

Study Description

Brief Summary

PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC).

SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time required to achieve it. To determine the duration of bacteriological response, defined as length of time that blood cultures remain sterile.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS
Study Start Date :
Jan 1, 1994
Actual Primary Completion Date :
Mar 1, 1995
Actual Study Completion Date :
Mar 1, 1995

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Patients must have:
    • History of HIV seropositivity.

    • Disseminated MAC.

    • Positive blood culture for MAC within 4 weeks prior to study entry.

    • Consent of parent or guardian if less than 18 years of age.

    • Ability to complete the study.

    NOTE:
    • Patients with active opportunistic infections other than dMAC are permitted if dosage and clinical parameters have been stable for 4 weeks prior to enrollment.

    Exclusion Criteria

    Concurrent Medication:
    Excluded:
    • Active therapy with carbamazepine or theophylline, unless investigator agrees to carefully monitor blood levels.

    • Active therapy with investigational drugs other than treatment for HIV disease, except with approval of the sponsor.

    • Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal).

    • Amikacin.

    • Azithromycin.

    • Capreomycin.

    • Ciprofloxacin.

    • Cycloserine.

    • Ethionamide.

    • Gentamicin.

    • Kanamycin.

    • Levofloxacin.

    • Lomefloxacin.

    • Ofloxacin.

    • Rifampin.

    • Rifabutin.

    • Sparfloxacin.

    • Streptomycin.

    • Any other aminoglycosides, quinolones, and macrolides.

    Patients with the following prior conditions are excluded:

    History of allergy or hypersensitivity to macrolides, ethambutol, or clofazimine.

    Prior Medication:
    Excluded:
    • Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other macrolides (such as clindamycin), quinolones, and rifampin, between screening and study entry.

    • Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more than 14 days cumulative within the past 2 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kaiser Permanente Med Ctr Los Angeles California United States 90027
    2 UCD Med Ctr Sacramento California United States 95817
    3 Kaiser Permanente Med Ctr San Francisco California United States 94115
    4 Santa Clara Valley Med Ctr San Jose California United States 951282699
    5 George Washington Univ Med Ctr Washington District of Columbia United States 20037
    6 Dr Margaret Fischel Miami Florida United States 33136
    7 Saint Joseph's Hosp / Infectious Disease Rsch Institute Tampa Florida United States 33614
    8 Rush Presbyterian - Saint Luke's Med Ctr Chicago Illinois United States 60612
    9 Tulane Univ Med School New Orleans Louisiana United States 701122699
    10 Johns Hopkins Univ School of Medicine Baltimore Maryland United States 21205
    11 Beth Israel Med Ctr New York New York United States 10003
    12 Mount Sinai Med Ctr New York New York United States 10029
    13 Univ of North Carolina School of Medicine Chapel Hill North Carolina United States 275997215
    14 Dr Stephen Hauptman Philadelphia Pennsylvania United States 19107
    15 Vanderbilt Univ School of Medicine Nashville Tennessee United States 37212
    16 Univ of Texas Southwestern Med Ctr of Dallas Dallas Texas United States 75235
    17 Houston Veterans Administration Med Ctr Houston Texas United States 77030
    18 Dr Javier Morales Condado San Juan Puerto Rico 00907

    Sponsors and Collaborators

    • Abbott

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002331
    Other Study ID Numbers:
    • 214A
    • M93-069
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jan 16, 2015
    Last Verified:
    Feb 1, 2009

    Study Results

    No Results Posted as of Jan 16, 2015